Amgen invests US$900M to grow Ohio biomanufacturing facility

USA—Amgen, a leading biotechnology company, has announced a major US$900 million expansion of its biomanufacturing facility in New Albany, Ohio.

This significant investment is set to add 350 new jobs, bringing the total number of Amgen employees in Ohio to 750.

With this latest commitment, Amgen’s overall investment in the state will surpass US$1.4 billion.

The New Albany facility, which officially opened in February 2024, is already recognized as the most advanced site in Amgen’s global operations network.

Spanning nearly 300,000 square feet, the plant currently employs 400 full-time staff and is designed to assemble and package medicines for patients worldwide.

Notably, the facility incorporates open workspaces to encourage collaboration and is built to meet stringent environmental standards, supporting Amgen’s pledge to achieve carbon neutrality across all operations by 2027.

Amgen’s decision to expand in Ohio is rooted in the state’s supportive business climate, skilled workforce, and strategic location.

Company CEO Robert A. Bradway emphasized that this investment reinforces Amgen’s ongoing commitment to expanding U.S. manufacturing and ensuring global access to innovative medicines.

 Ohio Governor Mike DeWine echoed these sentiments, highlighting the state’s strong foundation for economic development and its growing reputation as a premier destination for advanced manufacturing.

The economic impact of Amgen’s presence in Ohio is substantial.

Beyond job creation, the facility supports an annual payroll of US$40 million, benefiting local families and contributing to the region’s economic growth.

Furthermore, Amgen has partnered with Columbus State Community College to offer an 18-month manufacturing apprenticeship program.

This initiative is designed to provide opportunities for individuals new to the field or those changing careers, without requiring a four-year degree, thereby broadening access to high-quality jobs and fostering workforce diversity.

This expansion in Ohio comes shortly after Amgen opened a new drug substance facility in North Carolina, underscoring the company’s strategy to bolster its U.S. manufacturing footprint.

Amgen’s investments are part of a broader trend among pharmaceutical companies, many of which are increasing domestic production in response to evolving tax policies and the potential for industry-specific tariffs.

While some industry leaders argue that competitive tax policies are more effective than tariffs in promoting onshoring, Amgen’s ongoing investments underscore the significance of both a supportive business environment and government incentives in driving manufacturing growth.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.